Tamara Maes
Founder bei ORYZON GENOMICS S.A.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Tamara Maes is the founder of Oryzon Genomics SA, which was founded in 2000.
She currently holds the position of First Deputy Chairman at Oryzon Genomics SA. Dr. Maes is also currently working as a Director at Mendelion Lifesciences SL, a Member at the Alzheimers Drug Discovery Foundation, and a Scientific Coordinator at Oncnosis Pharma AIE.
Dr. Maes obtained a doctorate degree from Ghent University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ORYZON GENOMICS SA
4,08% | 31.12.2022 | 2 528 398 ( 4,08% ) | 5 Mio $ | 31.03.2024 |
Aktive Positionen von Tamara Maes
| Unternehmen | Position | Beginn |
|---|---|---|
| ORYZON GENOMICS S.A. | Founder | 02.06.2000 |
| Oncnosis Pharma AIE | Corporate Officer/Principal | - |
Mendelion Lifesciences SL
 Mendelion Lifesciences SL Engineering & ConstructionIndustrial Services Mendelion Lifesciences SL constructs commercial buildings. | Director/Board Member | - |
Alzheimers Drug Discovery Foundation
 Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Tamara Maes
| Ghent University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ORYZON GENOMICS S.A. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Health Technology |
| Oncnosis Pharma AIE | |
Mendelion Lifesciences SL
Mendelion Lifesciences SL Engineering & ConstructionIndustrial Services Mendelion Lifesciences SL constructs commercial buildings. | Industrial Services |
